Pathological adaptive responses of schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

GLIA

Volumn 58, Issue 16, 2010, Pages 1961-1976

  Shin, Yoon Kyung ^a   Jang, So Young ^a   Lee, Hyun Kyoung ^b   Jung, Junyang ^a   Suh, Duk Joon ^a   Seo, Su Yeong ^a   Park, Hwan Tae ^a  

^a Dong A University   (South Korea)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bortezomib; Endoplasmic reticulum stress; Microarray; Neuropathy; Remak bundle; Schwann cells

Indexed keywords

BORTEZOMIB; CHAPERONE; CXCL2 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; THAPSIGARGIN;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL STRESS; CONTROLLED STUDY; ENDONEURIUM; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; MYELINATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCHWANN CELL;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AXONS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; FEMALE; MACROPHAGES; MICE; MICE, INBRED C57BL; MYELIN PROTEINS; MYELIN SHEATH; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; PROTEIN UNFOLDING; PYRAZINES; SCHWANN CELLS; STRESS, PHYSIOLOGICAL;

EID: 78649421033     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21065     Document Type: Article

References (46)

1. Argyriou AA, Iconomou G, Kalofonos HP. 2008. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 112:1593-1599.
2. Birchmeier C, Nave KA. 2008. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 56:1491-1497.
3. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. 2006. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13:748-758.
4. Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X. 2010. Neurophysiological, histological and immu-nohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223:599-608.
5. Casafont I, Berciano MT, Lafarga M. 2010. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17:167-178.
6. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, De Coster R. 2007. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 204:317-325.
7. Cavo M. 2006. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20:1341-1352.
8. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. 2008. Characteristics of bortezomib-and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13:275-282.
9. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P. 2006. Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 26:9771-9779.
10. Dickson KM, Bergeron JJ, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ. 2002. Association of calnexin with mutant peripheral myelin protein-22 ex vivo: A basis for "gain-of-function" ER diseases. Proc Natl Acad Sci U S A 99:9852-9857.
11. Fischer S, Kleinschnitz C, Müller M, Kobsar I, Ip CW, Rollins B, Martini R. 2008. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol Cell Neurosci 37:359-366.
12. Fribley A, Zeng Q, Wang CY. 2004. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695-9704.
13. Gomez-Sanchez JA, Lopez de Armentia M, Lujan R, Kessaris N, Richardson WD, Cabedo H. 2009. Sustained axon-glial signaling induces Schwann cell hyperproliferation, Remak bundle myelination, and tumorigenesis. J Neurosci 29:11304-11315.
14. Hayakawa K, Hiramatsu N, Okamura M, Yamazaki H, Nakajima S, Yao J, Paton AW, Paton JC, Kitamura M. 2009. Acquisition of anergy to proinflammatory cytokines in nonimmune cells through endoplasmic reticulum stress response: A mechanism for subsidence of inflammation. J Immunol 182:1182-1191.
15. Jessen KR, Mirsky R. 2008. Negative regulation of myelination: Relevance for development, injury, and demyelinating disease. Glia 56:1552-1565.
16. Kao SC, Wu H, Xie J, Chang CP, Ranish JA, Graef IA, Crabtree GR. 2009. Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation. Science 323:651-654.
17. Kohl B, Fischer S, Groh J, Wessig C, Martini R. 2010. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-Tooth 1A neuropathy. Am J Pathol 176:1390- 1399.
18. Lee AS. 2001. The glucose-regulated proteins: Stress induction and clinical applications. Trends Biochem Sci 26:504-510.
19. Lee HK, Seo IA, Park HK, Park YM, Ahn KJ, Yoo YH, Park HT. 2007. Nidogen is a prosurvival and promigratory factor for adult Schwann cells. J Neurochem 102:686-698.
20. Lee HK, Seo IA, Suh DJ, Hong JI, Yoo YH, Park HT. 2009a. Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem 108:776-786.
21. Lee HK, Shin YK, Jung J, Seo SY, Baek SY, Park HT. 2009b. Protea-some inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. Glia 57:1825-1834.
22. Lee HK, Wang L, Shin YK, Lee KY, Suh DJ, Park HT. 2009c. Interleukin-6 induces proinflammatory signaling in Schwann cells: A high-throughput analysis. Biochem Biophys Res Commun 382:410-414.
23. Lin W, Popko B. 2009. Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci 12:379-385.
24. Martini R, Fischer S, López-Vales R, David S. 2008. Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia 56:1566-1577.
25. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G. 2010. Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343-350.
26. Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, Hickey WF, Kiefer R. 2003. Macrophage response to peripheral nerve injury: The quantitative contribution of resident and hematogenous macrophages. Lab Invest 83:175-185.
27. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ. 2005. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658-11666.
28. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. 2008. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094.
29. Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon LA, Woodhoo A, Lloyd AC, Feltri ML, Wrabetz L, Behrens A, Mirsky R, Jessen KR. 2008. c-Jun is a negative regulator of myelination. J Cell Biol 181:625-637.
30. Pennuto M, Tinelli E, Malaguti M, Del Carro U, D'Antonio M, Ron D, Quattrini A, Feltri ML, Wrabetz L. 2008. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 57:393-405.
31. Perrin FE, Lacroix S, Avilés-Trigueros M, David S. 2005. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 128:854-866.
32. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T, Goldsmith PC, Ellerby LM, Ellerby HM, Bredesen DE. 2002. Coupling endoplasmic reticulum stress to the cell death program: Role of the ER chaperone GRP78. FEBS Lett 514:122-128.
33. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M, Costa A. 2008. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 119:2507-2512.
34. Siebert H, Sachse A, Kuziel WA, Maeda N, Bruck W. 2000. The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol 110:177-185.
35. Skaug B, Jiang X, Chen ZJ. 2009. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 78:769-796.
36. Southwood CM, Garbern J, Jiang W, Gow A. 2002. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 36:585-596.
37. Svaren J, Meijer D. 2008. The molecular machinery of myelin gene transcription in Schwann cells. Glia 56:1541-1551.
38. Swanton E, Holland A, High S, Woodman P. 2005. Disease-associated mutations cause premature oligomerization of myelin proteolipid protein in the endoplasmic reticulum. Proc Natl Acad Sci U S A 102: 4342-4347.
39. Taskinen HS, Röyttä M. 2000. Increased expression of chemokines (MCP-1, MIP-1alpha, RANTES) after peripheral nerve transection. J Peripher Nerv Syst 5:75-81.
40. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL. 2005. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47:681-694.
41. Ulzheimer JC, Peles E, Levinson SR, Martini R. 2004. Altered expression of ion channel isoforms at the node of Ranvier in P0-deficient myelin mutants. Mol Cell Neurosci 25:83-94.
42. Utecht KN, Kolesar J. 2008. Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 65:1221-1231.
43. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR. 1998. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 18:382-384.
44. Xu W, Manichella D, Jiang H, Vallat JM, Lilien J, Baron P, Scarlato G, Kamholz J, Shy ME. 2000. Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J Neurosci Res 60:714-724.
45. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. 2004. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23:2009-2015.
46. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, Zhu Y. 2008. Induction of abnormal proliferation by nonmyelinating Schwann cells triggers neurofibroma formation. Cancer Cell 13:117-128.